Ophthalmic compositions comprising combinations of carbonic anhydrase inhibitors and S-(-)-1-(tert-butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yl)-oxy-2-propanol for topical application in the treatment of elevated intraocular pressure.

摘要

Although carbonic anhydrase inhibitors (C.A.I.) can be administered systemically by oral or intravenous routes, attempts to administer them topically have been ineffective and inactive in the treatment of intraocular hypertension. The alkali metal salts, especially the sodium and potassium salts, of salt-forming carbonic anhydrase inhibitors in combination with S-(-)-1- (tert-butylamino) -3-[(4-morpholino-1,2,5-thiadiazol -3-yl)oxy] -2-propanol or its racemic modification are now found to be remarkably effective in lowering intraocular pressure, even in normotensive hosts, but especially in those hosts having an elevated intraocular pressure.